About Contact Us Careers
Sign In

Vaccine Adjuvants Market Size & Share, by Product Type (Adjuvant Emulsions, Pathogen Components, Saponin-based Adjuvants, Particulate Adjuvants), Route of Administration (Intramuscular, Subcutaneous, Oral Route), Disease Type (Infectious Diseases, Cancer), Application (Research Application, Commercial Application), Application Category (Human, Veterinary) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4796
  • Published Date: Apr 08, 2023
  • Report Format: PDF, PPT

Companies Dominating the Vaccine Adjuvants Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GSK plc
    • SK Bioscience
    • Sanofi
    • Abbott
    • Phibro Animal Health Corporation
    • Astrazeneca
    • Novavax, Inc.
    • Agenus Inc.
    • Astellas Pharma Inc.
Browse Key Market Insights with Data Illustration:

In the News

  •  As the basis for their applications for regulatory approval, Sanofi and GSK plc intend to submit data from their booster and Phase 3 efficacy trials. The data they plan to submit is expected to include the full results of their Phase 3 efficacy trial of the vaccine, as well as data from their booster trial, which is designed to assess the efficacy of the vaccine after a booster dose.

  • GSK plc and SK Bioscience have submitted an application for a biologics license to the Korean Ministry of Food and Drug Safety for their SKYCovione after receiving positive Phase III clinical results. It is a candidate COVID-19 vaccine based on recombinant protein that has been adjuvant with GSK's pandemic adjuvant.

 


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4796
  • Published Date: Apr 08, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing prevalence of infectious diseases and the growing demand for safe and effective vaccines are the major factors driving the market growth.

The market size of vaccine adjuvants is anticipated to attain a CAGR of 4.70% over the forecast period, i.e., 2023-2035.

High cost of vaccine adjuvants and the complexities associated with their development, as well as stringent regulatory requirements are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., GSK plc, SK Bioscience, Sanofi, Abbott, Phibro Animal Health Corporation, Astrazeneca, Novavax, Inc., Agenus Inc., Astellas Pharma Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, route of administration, disease type, application, application category and by region.

The adjuvant emulsions segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying